About Exelixis

At Exelixis, our vision is to be a commercial world-class biotechnology company.

We believe that we can achieve this with an approach of focused excellence in everything that we do-in working efficiently, in making data-driven decisions quickly, and in advancing promising compounds rapidly. Already, we have built one of the most impressive oncology development pipelines in the biotechnology and pharmaceutical industries.

We are focusing our resources and development efforts exclusively on cabozantinib (XL184), our most advanced solely-owned product candidate, in order to maximize the therapeutic and commercial potential of this compound. We believe cabozantinib has the potential to be a high-quality, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. We have also established a portfolio of other novel compounds that we believe have the potential to address serious unmet medical needs.

Exelixis was founded and incorporated in 1994. The company completed its Initial Public Offering in April 2000, and Exelixis common stock is traded under the symbol EXEL on the Nasdaq Global Select Market. The company is headquartered in South San Francisco, California, and has over 200 dedicated employees who share a commitment to making a positive difference in the lives of patients with cancer and other serious diseases.